SEC Filing Summary: Medasorb Technologies Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Medasorb Technologies Corporation (noted as Cytosorbents Corp in metadata) on March 12, 2007, reporting an event dated February 25, 2007. The filing addresses a default condition related to the company's Series A 10% Cumulative Convertible Preferred Stock issued in June 2006.
Key Financial Metrics
The filing does not provide standard financial statements such as revenue, profit, or cash flow. However, it discloses specific financial obligations triggered by the default:
- Preferred Stock Issuance: 5,250,000 shares with an aggregate stated value of $5,250,000.
- Liquidated Damages: $105,000 per 30-day period (2% of purchase price) payable to investors starting February 26, 2007.
- Dividend Rate Increase: Accrual rate increased from 10% to 20% per annum on the stated value due to the default.
Material Changes
The primary material change is the occurrence of an "event of default" under the Certificate of Designation for the Series A Preferred Stock. This was triggered because the registration statement for the shares, which was required to be declared effective by February 25, 2007, had not yet been declared effective by the SEC. Consequently, the company is now obligated to pay liquidated damages and higher dividends.
Outlook, Risks, and Management Commentary
Management expects the registration statement to be declared effective no earlier than April 2007. Until that date, the company faces ongoing cash outflows for liquidated damages and increased dividend accruals. The filing highlights the risk of continued default status and the associated financial penalties.
Investor Verification Checklist
- Verify the current status of the SEC registration statement for the Series A Preferred Stock.
- Confirm the total accumulated liquidated damages and dividend accruals since February 26, 2007.
- Assess the company's liquidity position to determine its ability to meet the new 20% dividend rate and $105,000 periodic payments.
- Review the company's capital structure to understand the dilution impact if dividends are paid in additional shares.